Search results
Added:
3 months ago
Source:
Radcliffe Cardiology
The decision to switch frail, elderly patients with atrial fibrillation (AF) from a stable vitamin K antagonist (VKA) regimen to a direct-acting oral anticoagulant (DOAC) remains a subject of clinical debate. A new substudy from the COMBINE-AF dataset provides clarity, suggesting that while the switch reduces severe outcomes like stroke and death, it does not lower the risk of major bleeding and…
View more
Added:
1 year ago
AHA 23 - Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews Dr Christian Ruff (Brigham and Women's Hospital, US) on the late-breaking findings from the AZALEA-TIMI 71 randomized trial (Anthos Theraputics, Inc).AZALEA-TIMI 71 aimed to evaluate the bleeding profile of abelacimab as compared to rivaroxaban in patients with atrial fibrillation who are at moderate to…
View more
Added:
9 months ago
AF Symposium 25 - Left atrial appendage (LAA) closure using the WATCHMAN FLX device (Boston Scientific) showed lower risk of bleeding and non-inferiority in efficacy endpoints to oral anticoagulation in patients who have received or are planning to receive AF ablation.Dr Walid Saliba (Cleveland Clinic, OH, US) joins us onsite at AF Symposium 25 to discuss the findings from the concomitant and…
View more
AF Symposium 2025 Late-Breaking Science Collection
Video Series
AHA 25: The OCEAN Trial
Added:
5 days ago
Video
Added:
1 year ago
AHA 2023 - Investigator, Dr Mandeep Mehra (Brigham and Women's Hospital, US) is interviewed by Dr Christian Inchaustegui (Oregon Health & Science University, US), CardioNerds Ambassador, on the findings of the ARIES HM3 trial (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES…
View more
Added:
2 months ago
Source:
Arrhythmia Academy
Managing antithrombotic therapy in older patients with both atrial fibrillation (AF) and stable coronary artery disease (CAD) presents a clinical challenge, balancing the risks of thrombotic events and bleeding. A new post hoc analysis of the AFIRE trial sought to clarify whether the effects of rivaroxaban monotherapy differ across age groups compared to combination therapy with an antiplatelet…
View more
Added:
1 year ago
AHA 2023 — Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews investigator, Dr Jeff Healey (McMaster University, CA) to outline the findings from a phase 4 trial of apixaban to reduce thromboembolism in patients with subclinical atrial fibrillation (AF).ARTESiA (NCT01938248) aims to determine if apixaban in combination with aspirin can reduce the instance of…
View more
TCT 23: WATCH-TAVR
Added:
2 years ago
Video
Added:
2 years ago
ESC 2023 — Prof Paulus Kirchhof (University Heart & Vascular Center Hamburg, DE) discusses the findings of the NOAH-AFNET 6 trial (NCT02618577).
NOAH-AFNET 6 (Atrial Fibrillation Network, Daiichi Sankyo Europe) was an investigator-initiated, prospective, randomised trial aiming to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy in stroke prevention,…
View more